AUTHORS
Nicole Collaço, PhD, Jonathan Sive, MD2, Alan Chant3, Lorna Barnard4, Judit Kovac5, Catalina Quintero-Jaramilo6, Sophie Gillard7, Joanne Land, MSc8, David Cairns, PhD9, Kwee Yong, Prof10, Karthik Ramasamy, MD11, Catherine Olivier12, Kara-Louise Royle, PhD13, Sharon Jackson14, Abigail Fisher, PhD15, Orla McCourt, PhD16
AFFILIATIONS
1 University College London, London, United Kingdom
2 University College London Hospitals NHS Foundation Trust, London, United Kingdom
3 Patient Representative, Leeds, United Kingdom
4 University of Leeds, Leeds, United Kingdom
5 University College London, London, United Kingdom
6 University College London, London, United Kingdom
7 University College London, London, United Kingdom
8 University College London Hospitals NHS Foundation Trust, London, United Kingdom
9 University of Leeds, Leeds, United Kingdom
10 University College London, London, United Kingdom
11 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
12 University of Leeds, Leeds, United Kingdom
13 University of Leeds, Leeds, United Kingdom
14 University of Leeds, Leeds, United Kingdom
15 University College London, London, United Kingdom
16 University College London Hospitals NHS Foundation Trust, London, United Kingdom, University College London, London, United Kingdom
ABSTRACT
Introduction
RADAR is a randomised controlled trial (RCT) investigating different treatment combinations to improve outcomes for people newly diagnosed with myeloma. Participants are allocated to different treatment groups based on the genetic characteristics of their myeloma and their response to initial treatment. RADIUS (RADar attItUdeS) is a sub-study of RADAR and aims to understand trial participants’ experiences of receiving information about genetic risk and minimal residual disease (MRD) results, and their views on treatment tailored to these results.
Methods
RADIUS was conceived through collaboration with the RADAR trial patient advisory group (PAG). Participants were recruited through the RADAR trial via participating hospital sites across the United Kingdom. Within the RADAR trial information and consent document, participants were given the option to indicate whether they agreed to be contacted with further information about patient experience interviews. Those who assented were provided with an additional study information sheet and consent form and invited to participate in semi-structured qualitative telephone interviews. The interview guide was developed with the PAG and explored participants’ understanding of trial information, as well as their experiences of receiving information about genetic risk and MRD. Interview data were analysed using the Framework Method.
Results
Sixty-nine participants were interviewed. Three themes were identified: 1) Variable recall and comprehension of personalised test results; participants demonstrated variable understanding of genetic risk testing, with most showing a basic understanding of its role in informing treatment pathways but limited and inconsistent understanding of what the test was or what the results meant. Understanding of genetic risk was often simplified to broad distinctions between ‘high’ and ‘standard risk’, with occasional misclassification by participants of their own risk status. Understanding of MRD testing was generally better, with participants viewing it as an indicator of treatment response. However, understanding of how genetic risk and MRD results determined trial treatment allocation was inconsistent. While some recognised that treatment pathways were personalised according to test results, others were unclear how treatment decisions were made, often deferring to healthcare professionals; 2) Communicating genetic risk and MRD results required more than disclosure: providing interpretation and opportunities to revisit information; participants valued clear, in person communication when given test results, with opportunities to revisit information, as limited explanations and the burden of diagnosis itself affected participant’s ability to retain information, and 3) Reconciling treatment preferences and responses to randomised allocation; among randomised participants, treatment preferences were influenced by the perceived intensity and type of treatment. Less intensive, oral tablets was generally preferred due to being viewed as more compatible with returning to work, managing family and caring responsibilities, and reducing disruption to daily life. Although some expressed disappointment when allocated to a non-preferred treatment arm, most ultimately accepted randomisation, trusting the trial process and valuing the additional monitoring provided.
Conclusion
Participants’ understanding of genetic risk, MRD results, and their role in treatment allocation varied considerably. Findings highlight the challenge of communicating personalised treatment approaches in the context of a new myeloma diagnosis, where participants must process complex information alongside adjusting to a life-changing diagnosis, treatment decisions, and trial procedures. Supporting meaningful understanding of these test results requires clear, ongoing communication with trusted healthcare/trial professionals to help participants understand how their individual results relate to their treatment pathway, while recognising the important role of trust in healthcare professionals and the clinical trial process. These findings have implications for the design and delivery of future complex clinical trials, as well as routine clinical care, where communicating personalised and often difficult to understand medical information is important.
DISCLOSURES
Orla McCourt, PhD: Gilead Sciences - Consultancy (Includes expert testimony); Janssen-Cilag Ltd, a Johnson & Johnson Company - Consultancy (Includes expert testimony)